IN 003
Alternative Names: IN-003Latest Information Update: 22 Mar 2024
At a glance
- Originator Inhalon Biopharma
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Metapneumovirus infections
Most Recent Events
- 22 Mar 2024 Inhalon Biopharma plans clinical trial in Metapneumovirus infections in USA (Inhalation)
- 20 Mar 2024 Inhalon Biopharma has patent protection for composition of aerosolized muco-trapping antibodies in USA and European Union
- 26 Sep 2023 Early research in Metapneumovirus infections in USA (Inhalation) prior to September 2023 (Inhalon Biopharma pipeline, September 2023)